Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?
OBJECTIVE
It remains uncertain whether current smoking influences outcome in patients with acute ischaemic stroke.


OBJECTIVE
To evaluate the effect of current smoking in routinely tissue plasminogen activator (tPA)-treated stroke patients on the 3-month functional outcome and the occurrence of symptomatic intracerebral hemorrhage (ICH).


METHODS
We analyzed data from a single stroke care unit registry of 345 consecutive patients with ischaemic stroke, treated with tPA. Logistic regression models were used to assess if smoking was independently associated with 3-months good outcome defined as a modified Rankin Scale score of < or =2, and the occurrence of symptomatic ICH.


RESULTS
In the multivariable models, smoking was not associated with a good outcome or a decreased risk of symptomatic ICH.


CONCLUSIONS
Current smoking did not affect functional outcome at 3 months or the risk of symptomatic ICH in patients routinely treated with tPA for ischaemic stroke.
Aries
M J H
MJ
Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands. m.j.h.aries@neuro.umcg.nl
Uyttenboogaart
M
M
Koch
M W
MW
Langedijk
M
M
Vroomen
P C
PC
Luijckx
G J
GJ
De Keyser
J
J
D000368:Aged; D000369:Aged, 80 and over; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous / Q000379:methods; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012907:Smoking / Q000009:adverse effects*; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator